Sara De Santis
Bologna, 40138, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Venetoclax plus azacitidine as genetic-driven bridge-to-transplant therapy for IDH2-mutated acute myeloid leukaemia (AML) refractory to intensive chemotherapy: proof-of-concept case reports.
Journal: Annals of hematology
Published: May 11, 2025
Tracking Response and Resistance in Acute Myeloid Leukemia through Single-Cell DNA Sequencing Helps Uncover New Therapeutic Targets.
Journal: International journal of molecular sciences
Published: July 30, 2024
SETD2 loss of function is a recurrent event in advanced-phase chronic myeloid leukemia and contributes to genomic instability: SETD2 loss in Chronic Myeloid Leukemia.
Journal: Clinical and translational medicine
Published: June 10, 2024
Unstable major molecular response as a trigger for next generation sequencing-based BCR::ABL1 mutation testing in chronic myeloid leukemia.
Journal: American journal of hematology
Published: September 15, 2023
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted.
Journal: Biomarker research
Published: December 15, 2022
Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia.
Journal: Leukemia
Published: March 24, 2022
Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors.
Journal: Frontiers in oncology
Published: March 21, 2022
Combined Inhibition of Polo-Like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells.
Journal: Cancers
Published: December 13, 2021
Overcoming Resistance to Kinase Inhibitors: The Paradigm of Chronic Myeloid Leukemia.
Journal: OncoTargets and therapy
Published: November 10, 2021
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia.
Journal: Frontiers in oncology
Published: June 21, 2021
Targeting Leukemic Stem Cells in Chronic Myeloid Leukemia: Is It Worth the Effort?
Journal: International journal of molecular sciences
Published: May 29, 2021
Last Updated: 09/26/2026